Key result
Network pharmacology links Dan-Lou tablets to ~79 candidate target genes in hyperlipidemia-associated CHD.
Answers are grounded in this paper and cite their sources.
Network pharmacology and transcriptomic analysis suggests Dan-Lou tablets may target lipid metabolism and macrophage-associated inflammatory pathways in hyperlipidemia-associated coronary heart disease.
Coronary heart disease (CHD) is closely associated with dyslipidemia-driven atherosclerosis, in which macrophage-mediated inflammation links lipid deposition to plaque progression. Dan-Lou tablets (DLT), a traditional Chinese medicine preparation used clinically for CHD, have been reported to affect lipid and inflammatory pathways. This study aimed to identify candidate targets and pathways of blood-absorbed DLT constituents in hyperlipidemia-associated CHD and macrophage-associated inflammatory contexts. Six blood-absorbed constituents of DLT (puerarin, formononetin, calycosin, paeoniflorin, tanshinone IIA, and cryptotanshinone) were investigated using an integrated network pharmacology and public transcriptomic strategy. Compound-related targets from TCMSP were intersected with hyperlipidemia-related genes from GeneCards, followed by enrichment analysis, protein-protein interaction analysis, macrophage-infiltration correlation analysis, GeneMANIA network analysis, and validation using the Gene Expression Omnibus dataset GSE179789. A total of 117 compound targets and 3,449 hyperlipidemia-related genes yielded 79 intersecting genes. Enrichment analysis highlighted lipid and atherosclerosis, interleukin signaling, fluid shear stress and atherosclerosis, AGE-RAGE signaling, hormone-related responses, and JAK-STAT-related pathways. Twenty-two genes showed relatively strong associations with inferred macrophage infiltration in the exploratory TCGA-LIHC analysis. CAV1, PTGIS, KLF9, and BCL2 showed differential expression in peripheral blood mononuclear cells from CHD patients before and after DLT treatment in GSE179789. DLT may influence hyperlipidemia-associated CHD through candidate targets linked to lipid metabolism and macrophage-associated inflammatory pathways. Because the present work is based mainly on in silico prediction and public-dataset validation, the findings should be regarded as hypothesis-generating and require further experimental validation, particularly direct assessment of macrophage phenotype and function.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied Hyperlipidemia-Associated Coronary Heart Disease. Dan-Lou tablets (DLT) constituents was evaluated on Candidate targets and pathways. Network pharmacology and transcriptomic analysis identified 79 intersecting genes, highlighting CAV1, PTGIS, KLF9, and BCL2 as candidate targets for Dan-Lou tablets in hyperlipidemia-associated CHD.
Synapse has enriched 10 related papers. Consider them for comparative context: